SCHEMBL1646174

SCHEMBL1646174

Cc1cc([C@@H](C)NC(=O)c2ccc3cc(N4CCCCC4)ccc3c2)ccc1NS(C)(=O)=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 1/20 0.42
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40
MCL1 Q07820 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ADRB2 P07550 3/20 0.40
ADRB3 P13945 3/20 0.40
ADRB1 P08588 2/20 0.40
RAD52 P43351 1/20 0.39
EPHX2 P34913 2/20 0.39
NR1H4 Q96RI1 2/20 0.39
DRD2 P14416 1/20 0.39
ADRA1A P35348 1/20 0.39
DRD3 P35462 1/20 0.39
KEAP1 Q14145 1/20 0.39
NFE2L2 Q16236 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1285209 0.99 GFER (0.42) GFERMEN1NPC1POLBMAPT
SCHEMBL1645472 0.97 GFER (0.41) GFERMEN1NPC1POLBMAPT
SCHEMBL1645249 0.91 UBE2N (0.46) MEN1MAPTKMT2AADRB2ADRB3
SCHEMBL1643038 0.86 ACACB (0.46) GFERMEN1NPC1POLBMAPT
SCHEMBL1644482 0.85 ACACB (0.47) GFERMEN1NPC1POLBMAPT
SCHEMBL1285476 0.83 KDM4E (0.48) MEN1NPC1RAB9AKMT2ADRD2
SCHEMBL1643824 0.83 ACACB (0.47) GFERMEN1NPC1POLBMAPT
SCHEMBL1285292 0.81 DHODH (0.48) KMT2ASMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL1285010 0.81 KMT2A (0.44) MEN1NPC1KMT2AKDM4EALDH1A1
SCHEMBL1285407 0.81 CNR1 (0.49) MEN1NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088746-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME PFIZER INC. (US) 2012-04-12 US disclosed
US-20120088746-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME PFIZER INC. (US) 2012-04-12 US disclosed
WO-2007133637-A2 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME RENOVIS, INC. (US) 2007-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088746-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME TRPV1, TRPA1, TRPV2 GFER 2099/4885MEN1 4500/4885NPC1 879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.